Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04913480 | SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 37 | The University of Hong KongOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | unknown | Phase 2 / Phase 3 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| Jun 2, 2021 |
| clinicaltrials |
| NCT02964260 | RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma | unknown | N/A | 410 | Sun Yat-sen UniversityOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04517227 | The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD) | unknown | N/A | 30 | Fudan UniversityOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT04641923 | The Efficacy of a Topical Anti-adhesive Film for Decreasing Perihepatic Adhesions in Repeat Hepatic Surgery | unknown | N/A | 40 | University of CalgaryOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02556619 | Randomized Control Trial (RCT) of Early Palliative Care for HCC | unknown | N/A | 72 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04814030 | Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial(AIPD-1) | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT03342677 | Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility | unknown | N/A | 80 | University Health Network, TorontoOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03971201 | A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion | unknown | Phase 2 | 200 | White Plains HospitalOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT04812054 | Dual Hypothermic Oxygenated Machine Perfusion in Liver Transplantation Using Allografts From Donors After Brain Death | unknown | N/A | 104 | Medical University of WarsawOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04834986 | Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | unknown | Phase 2 | 40 | Hunan Cancer HospitalOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04167293 | Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)(ISBRT01) | unknown | Phase 2 / Phase 3 | 116 | Mian XIOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT02806076 | RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode | unknown | N/A | 100 | Seoul National University HospitalOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04803019 | Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma(RAD-18-TAcE) | unknown | Phase 3 | 154 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02854241 | Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance | unknown | N/A | 40 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03742453 | Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis | unknown | N/A | 117 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04331184 | RFA Using Combined Bipolar and Monopolar Energy Deliver With Twin Cooled-Wet Electrodes | unknown | N/A | 102 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04471272 | RFA Using Gradual RF Energy Delivery Mode With Octopus Electrodes | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04665609 | Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC | unknown | Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04121273 | GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC | unknown | Phase 1 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04042805 | Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Baocai XingOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02786342 | Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib(INNOVATE) | unknown | — | 160 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04773769 | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas | unknown | N/A | 54 | Auxilio Mutuo Cancer CenterOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04170179 | Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04764409 | Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors(PATOC) | unknown | — | 500 | Central Clinical Hospital RZD-Medicine, Russian FederationOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04229355 | DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma | unknown | Phase 3 | 90 | Guangxi Medical UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04708483 | DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria | unknown | N/A | 100 | HyperfusionINDUSTRY | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04741165 | Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 72 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04738188 | Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; | unknown | N/A | 226 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04739501 | Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors | unknown | — | 100 | Assiut UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03146637 | Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer | unknown | Phase 2 | 80 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04730388 | ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or(HEPATOFIT) | unknown | — | 100 | University Hospital, BrestOTHER | 0 | Jan 29, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | unknown | Phase 1 | 10 | Liang PengOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04705194 | Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging(HEPARIM) | unknown | — | 134 | University of LeedsOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04107324 | ARAPS Study on Accelerated Liver Regeneration(ARAPS) | unknown | N/A | 30 | University of AarhusOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04479527 | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 34 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 14, 2021 | clinicaltrials |
| NCT04687163 | Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04183088 | Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 125 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04677088 | TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation | unknown | Phase 1 | 7 | Xiaoshun HeOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04640116 | TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites | unknown | N/A | 30 | Sun Yat-sen UniversityOTHER | 0 | Dec 19, 2020 | clinicaltrials |
| NCT04667351 | HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03475966 | Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program | unknown | N/A | 60 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04653701 | Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC | unknown | — | 30 | Juan José Ciampi DopazoOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04652492 | Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 72 | Zhongda HospitalOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04619342 | Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) | unknown | N/A | 98 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2021source: clinicaltrials